Stocktoria
ArriVent BioPharma, Inc. AVBP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-01-26
ArriVent BioPharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $153.4M | $79.0M | $64.9M |
| Operating income | -$177.5M | -$94.3M | -$74.6M |
| Net income | -$166.3M | -$80.5M | -$69.3M |
| EPS (diluted) | $-4.32 | $-2.56 | $-32.38 |
| Operating cash flow | -$160.6M | -$70.2M | -$55.8M |
| Cash & equivalents | $45.5M | $74.3M | $150.4M |
| Total assets | $333.2M | $274.9M | $163.1M |
| Total liabilities | $25.9M | $17.3M | $11.8M |
| Shareholders' equity | $307.2M | $257.7M | -$153.2M |
Source: SEC EDGAR filings · CIK 0001868279 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.